The Spanish Association Against Cancer (AECC) has granted two important sums to help researchers at the Spanish National Cancer Research Centre (CNIO) advance our knowledge of pancreatic cancer and lymphomas, with the aim of developing novel therapeutic modalities and to improve early diagnosis of these diseases.
One of the projects will be coordinated by the researcher Mariano Barbacid, head of CNIO’s Experimental Oncology Group, who together with Alfredo Carrato, head of the Oncology Department at the Ramón y Cajal Hospital in Madrid, and Bruno Sainz, head at the Autonomous University of Madrid, are focusing their research efforts on pancreatic adenocarcinoma (PDAC). The grant, totalling 1.2 million euros, is part of the Stable Coordinated Groups system, aimed at “promoting state-of-the-art cancer research, coordinated by various teams, following a common thread”, explains the AECC on its website.
Pancreatic adenocarcinoma (PDAC) is the fourth cause of cancer-related mortality worldwide. Although its incidence is not very high, only 7.2% of patients survive more than 5 years after the initial diagnosis. These statistics are due to metastasis; pancreatic cancer tends to spread to other organs, such as the liver, significantly reducing the chances of a cure.